Acute emesis: moderately emetogenic chemotherapy

On the receiving end—patient perception of the side-effects of cancer chemotherapy

Alan S. Coates, Suzanne Abraham, S.B. Kaye et al. · European Journal of Cancer and Clinical Oncology · 1983 · 1K citations

Palliative Care, Medicine, Cancer Management +8

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

Paul J. Hesketh, Steven M. Grunberg, Richard J. Gralla et al. · Journal of Clinical Oncology · 2003 · 770 citations

American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006

Mark G. Kris, Paul J. Hesketh, Mark R. Somerfield et al. · Journal of Clinical Oncology · 2006 · 742 citations · Full text

Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines

Richard J. Gralla, David Osoba, Mark G. Kris et al. · Journal of Clinical Oncology · 1999 · 670 citations

Preclinical Therapeutics, Perioperative Medicine, Evidence-based Medicine +27

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting

S. Poli-Bigelli, José Rodrigues-Pereira, Alexandra D. Carides et al. · Cancer · 2003 · 566 citations